These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37149113)

  • 21. Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches.
    Dua K; Rapalli VK; Shukla SD; Singhvi G; Shastri MD; Chellappan DK; Satija S; Mehta M; Gulati M; Pinto TJA; Gupta G; Hansbro PM
    Biomed Pharmacother; 2018 Nov; 107():1218-1229. PubMed ID: 30257336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis.
    Sheikh BA; Bhat BA; Mehraj U; Mir W; Hamadani S; Mir MA
    Curr Pharm Biotechnol; 2021; 22(4):480-500. PubMed ID: 32600226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Host-targeted therapy for tuberculosis: Time to revisit the concept.
    Desikan P; Rangnekar A
    Indian J Med Res; 2018 Mar; 147(3):233-238. PubMed ID: 29923511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of Multi-Drug Resistant
    Ali S; Khan MT; Khan AS; Mohammad N; Khan MM; Ahmad S; Noor S; Jabbar A; Daire C; Hassan F
    Pol J Microbiol; 2020; 69(2):1-5. PubMed ID: 32249555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk Factors for Multidrug-resistant Tuberculosis.
    Rumende CM
    Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current advances in the clinical development of anti-tubercular agents.
    Tetali SR; Kunapaeddi E; Mailavaram RP; Singh V; Borah P; Deb PK; Venugopala KN; Hourani W; Tekade RK
    Tuberculosis (Edinb); 2020 Dec; 125():101989. PubMed ID: 32957054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanotechnology and tuberculosis: An old disease with new treatment strategies.
    Macêdo DCDS; Cavalcanti IDL; Medeiros SMFRDS; Souza JB; Lira Nogueira MCB; Cavalcanti IMF
    Tuberculosis (Edinb); 2022 Jul; 135():102208. PubMed ID: 35567896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Tubercular Activity of Pyrazinamide Conjugates: Synthesis and Structure-Activity Relationship Studies.
    Wahan SK; Sharma S; Chawla PA
    Mini Rev Med Chem; 2023; 23(6):700-718. PubMed ID: 35986542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB.
    Sankhe K; Khan T; Bhavsar C; Momin M; Omri A
    Expert Opin Drug Deliv; 2019 May; 16(5):525-538. PubMed ID: 31007100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel therapeutic approaches for targeting TB and HIV reservoirs prevailing in lungs.
    Jadhav M; Khan T; Bhavsar C; Momin M; Omri A
    Expert Opin Drug Deliv; 2019 Jul; 16(7):687-699. PubMed ID: 31111766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cursed duet today: Tuberculosis and HIV-coinfection.
    Tiberi S; Carvalho AC; Sulis G; Vaghela D; Rendon A; Mello FC; Rahman A; Matin N; Zumla A; Pontali E
    Presse Med; 2017 Mar; 46(2 Pt 2):e23-e39. PubMed ID: 28256380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    Respir Med; 2009 Dec; 103(12):1777-90. PubMed ID: 19660927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.
    Grotz E; Tateosian N; Amiano N; Cagel M; Bernabeu E; Chiappetta DA; Moretton MA
    Pharm Res; 2018 Sep; 35(11):213. PubMed ID: 30238168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
    Bhat ZS; Rather MA; Maqbool M; Ahmad Z
    Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies.
    Borah P; Deb PK; Venugopala KN; Al-Shar'i NA; Singh V; Deka S; Srivastava A; Tiwari V; Mailavaram RP
    Curr Top Med Chem; 2021; 21(6):547-570. PubMed ID: 33319660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets.
    Alsayed SSR; Gunosewoyo H
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982277
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.